



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

## Pioglitazone Actavis

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
IG/1612	A.1 - Administrative change - Change in the name and/or address of the MAH	31/05/2023		SmPC, Labelling and PL	
IAIN/0016/G	This was an application for a group of variations.	26/04/2021	24/06/2021	SmPC, Annex II and PL	

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	<p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release</p>				
IB/0015/G	<p>This was an application for a group of variations.</p> <p>B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p>	12/08/2020	n/a		
WS/1791	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>The RMP was updated to the RMP template rev 2 as per GVP module V rev 2, and the existing additional risk minimisation measures (educational pack for the healthcare professionals containing a prescriber guide) were removed both from the RMP and their key elements from the Annex IID of the PI, in line with the originator product for pioglitazone. In addition, standard wording was reinstated for the</p>	11/06/2020	24/06/2021	Annex II	

	<p>PSUR submission requirement with a reference to the updates included in the EURD list.</p> <p>C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required</p>				
IAIN/0013/G	<p>This was an application for a group of variations.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)</p>	07/01/2020	n/a		
N/0012	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	20/03/2018	24/06/2021	PL	
N/0011	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	09/08/2017	24/06/2021	Labelling and PL	
R/0009	Renewal of the marketing authorisation.	15/09/2016	11/11/2016		Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Pioglitazone Actavis in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.

IB/0010/G	<p>This was an application for a group of variations.</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p>	30/09/2016	14/11/2016	SmPC, Labelling and PL	
IA/0008	A.7 - Administrative change - Deletion of manufacturing sites	03/06/2016	n/a		
IAIN/0007/G	This was an application for a group of variations.	03/03/2016	n/a		

	A.7 - Administrative change - Deletion of manufacturing sites B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer				
N/0006	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	11/12/2015	11/11/2016	PL	
IAIN/0005	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	20/07/2015	n/a		
N/0004	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	18/02/2015	11/11/2016	PL	
IB/0003	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	06/03/2014	n/a		
IB/0002	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	12/12/2013	11/11/2014	SmPC and PL	
IB/0001	C.I.2.a - Change in the SPC, Labelling or PL of a	08/11/2013	11/11/2014	SmPC, Annex	

	generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH			II, Labelling and PL	
--	--	--	--	----------------------	--